Table 1.

Summary of clinical trials with PET and SPECT radiotracers targeting HER2-positive breast cancer

Radiotracer	Description of Trial	Clinical Trial or Reference	Sponsor	Status
89Zr-DFO-trastuzumab	HER2+ BC	NCT01832051	University Medical Center Groningen	Completed
	Imaging the effect of HSP90 inhibition	NCT01081600	University Medical Center Groningen	Completed
	HER2+ MBC	NCT01420146	Jules Bordet Institute	Completed
	HER2+ BC	NCT02065609	Washington University School of Medicine	Recruiting
	HER2+ MBC	NCT02286843	Memorial Sloan Kettering Cancer Center	Recruiting
	IMPACT-MBC	NCT01957332	University Medical Center Groningen	Recruiting
64Cu-DOTA-trastuzumab	HER2+ MBC	NCT00605397	Memorial Sloan Kettering Cancer Center	Completed
	Predicting treatment response in HER2+ BC	NCT02827877	City of Hope Medical Center	Verified
111In-CHX-A DTPA- trastuzumab	HER2+ BC	NCT01445054	National Cancer Institute	Completed
111In-MxDTPA- trastuzumab	HER2+ BC	Wong et al,49 2010	City of Hope Medical Center	Completed
	HER2+ MBC	Perik et al,47 2006	University Medical Center Groningen	Completed
	HER2+ MBC	Gaykema et al,48 2014	University Medical Center Groningen	Completed
68Ga-F(ab′)2- trastuzumab	HER2+ BC	NCT00613847	Memorial Sloan Kettering Cancer Center	Completed
68Ga-ABY-025	HER2+ BC	NCT01858116	Biomedical Radiation Sciences	Completed
	HER2+ BC	NCT02095210	Dorte Nielsen	Recruiting
111In-ABY-025	HER2+ MBC	NCT01216033	Biomedical Radiation Sciences	Completed
64Cu-MM-302	HER2+ MBC	NCT02735798	University of California, San Francisco	Verified
[131I]-SGMIB anti- HER2 VHH1	Healthy Patients and HER2+ BC	NCT02683083	Camel-IDS NV	Recruiting
68Ga-HER2-Nanobody	HER2+ BC	EudraCT 2012- 001135-31	Vrije Universiteit Brussels	Completed

Abbreviations: BC, breast cancer; HER2, human epidermal growth factor 2; IMPACT, IMaging PAtients for Cancer Drug selecTion; MBC, metastatic breast cancer; SGMIB, N-succinimidyl 4-guanidinomethyl 3-iodobenzoate; SPECT, single photon emission computed tomography.